Nektar Therapeutics (NKTR)
Nektar Therapeutics Cash and ST Investments: 382.11M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NKTR Cash and ST Investments Rankings
| Overall | 77th percentile | 978 of 4371 |
| Sector | 86th percentile | 70 of 504 in Healthcare |
| Industry | 91st percentile | 14 of 160 in Biotechnology |
NKTR Cash and ST Investments Range, Past 5 Years
| Minimum | 241.17M | Dec 2011 |
| Maximum | 518.64M | Mar 2011 |
| Average | 361.70M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these NKTR related companies
NKTR News
Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) Downgraded
May 24, 11:25AM Street Insider
May 24, 11:25AM Street Insider
Jefferies Starts Dendreon (DNDN) at Underperform, Nektar (NKTR) at Buy
May 22, 5:21PM Street Insider
May 22, 5:21PM Street Insider
Listen to $NKTR Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3dPo
about 28 days ago by earningscast
about 28 days ago by earningscast
Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
May 02, 4:15PM PR Newswire
May 02, 4:15PM PR Newswire
$NKTR filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aex
about 30 days ago by MarketBrief
about 30 days ago by MarketBrief
RT @BenCBanks $WHR looks good too now, and so does $NKTR (if it beraks)
about 37 days ago by Mortiman
about 37 days ago by Mortiman
$NKTR - beatiful set up in my opinion. #bullmarket #shortsqueeze http://chart.ly/nj9y29p
about 37 days ago by BenCBanks
about 37 days ago by BenCBanks
Listen to $NKTR investor and analyst r&d day - live at 12:00 PM, ondemand after - http://stks.co/3MZF
about 45 days ago by earningscast
about 45 days ago by earningscast
$NKTR released news of the partnership with $AFFY FDA approval on anemia drug.Technical setup shows momentum.I'm expecting a pop today.
about 64 days ago by stellarpicks
about 64 days ago by stellarpicks
Strong move in $NKTR today. I profiled the peculiar technical setup last night in this post: http://stks.co/36CZ
about 65 days ago by chessNwine
about 65 days ago by chessNwine
$NKTR going green. Waiting for $AFFY to explode to go along with the ride. Keep our fingers crossed with FDA decision today.
about 65 days ago by stellarpicks
about 65 days ago by stellarpicks
$NKTR has two lotto plays.$AFFY is the bigger of the two drugs. I see pullback in the morning from MAPP results, then rally rest of day.
about 65 days ago by stellarpicks
about 65 days ago by stellarpicks
NEW POST: "Wolf in Sheep's Dojis" http://stks.co/35YB $IBB $NKTR $QQQ $SPY $STUDY
about 65 days ago by chessNwine
about 65 days ago by chessNwine
RT @GArgondizza @odyssea WEIRD <<<I know so wht now $NKTR up AH after this release I dont trust it>>
about 65 days ago by odyssea
about 65 days ago by odyssea
$NKTR weak on rumored $MAPP FDA rejection, would get royalties if approved. Watch for action when official $MAPP PR comes.
about 66 days ago by TradeHawk
about 66 days ago by TradeHawk
Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay
Mar 20, 10:15AM PR Newswire
Mar 20, 10:15AM PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
Feb 29, 4:15PM PR Newswire
Feb 29, 4:15PM PR Newswire
Nektar (NKTR) to Sell Royalties for CIMZIA, MIRCERA to Royalty Pharma for $124M
Feb 29, 9:06AM Street Insider
Feb 29, 9:06AM Street Insider
Nektar (NKTR) reports agreement to sell Cimzia(R) and Mircera(R) royalties to Royalty Pharma for $124M
Feb 29, 8:31AM Street Insider
Feb 29, 8:31AM Street Insider
UPDATE: Bank of America Downgrades Nektar Therapeutics to Underperform, Maintains $6 PT
Jan 20, 9:02AM Benzinga
Jan 20, 9:02AM Benzinga
BofA/Merrill Lynch Downgrades Nektar Therapeutics (NKTR) to Underperform
Jan 20, 7:02AM Street Insider
Jan 20, 7:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NKTR | 6.87 | -0.18 | -2.55% | 807.44M |
| NKSH | 29.00 | -0.96 | -3.20% | 207.92M |
| NKO | 14.93 | +0.05 | +0.32% | |
| NKE | 108.61 | -2.31 | -2.08% | 50.84B |
| NKBP | 4.50 | -0.16 | -3.43% | 89.66M |
| NKA | 11.67 | -0.28 | -2.34% | 412.16M |
| NJR | 41.80 | -0.82 | -1.92% | 1.768B |
| NGSX | 0.37 | +0.00 | +0.00% | 11.07M |
| NGPC | 6.71 | +0.03 | +0.45% | 144.49M |
| NGLS | 40.45 | -0.92 | -2.22% | 3.764B |